Log in

Company updateBusinessLine

Sanofi India MD outlines growth plans for rare disease

Positive+19

GreyOak summary

Sanofi India MD Deepak Arora stated the company has no fear of missing out on the GLP-1 category due to its Soliqua product. The company plans to scale access in rare diseases and diabetes, with a new haemophilia therapy launching next year. Public sector purchases contributed nearly 85% growth in the last quarter through government health programs.

What it affects

  • Sanofi IndiaSANOFIPositive +19

    Plans to scale rare disease and diabetes access.Rolling sentiment Neutral +11

Source

Read the original at BusinessLine

More Sanofi India news

No other recent stories about Sanofi India.

All Sanofi India news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy